SEHK:1477Pharmaceuticals
Ocumension Therapeutics (SEHK:1477) Stock Growth Story Runs Into Funding Risk
Ocumension Therapeutics walked into this earnings season with a growth story and a stock that had drifted over the past three months, down about 14.5%, yet roughly flat over the week and modestly firmer over the month. The headline today is not revenue; it is the pressure on the income statement. H1 2026 brought a net loss of C¥99.0 million and basic earnings per share of C¥0.12 loss, keeping profitability out of reach and sharpening investor focus on how long the company can fund its...